Helicobacter pylori in Children – Dermatological Manifestations, Examination
Table of Contents 3
Helicobacter pylori infection in pediatric populations: Epidemiological distribution, pathogenic mechanisms, and clinical implications
Cutaneous manifestations associated with *Helicobacter pylori* infection: Clinical correlations, emerging evidence, and diagnostic controversies
Diagnostic assessment for Helicobacter pylori infection: methodologies and clinical implications
The diagnosis of Helicobacter pylori infection relies on two primary categories of diagnostic assessments: invasive procedures, which necessitate upper gastrointestinal endoscopy (gastroscopy), and non-invasive methods. Invasive techniques include the rapid urease test (detecting the bacterial enzyme urease), histopathological examination (microscopic analysis of gastric mucosal biopsies), and microbial culture (cultivating the bacterium to identify strain-specific characteristics and antibiotic susceptibility profiles).
Among non-invasive approaches, the urea breath test (UBT) using isotopically labeled urea (^13C or ^14C) is widely regarded as the "gold standard" for confirming active infection. The procedure involves administering a solution containing labeled urea, which—upon exposure to bacterial urease—decomposes into ammonia and labeled carbon dioxide (CO₂). After 30 minutes, an exhaled breath sample is collected, and the concentration of labeled CO₂ correlates with the presence of H. pylori. This test demonstrates exceptional sensitivity (probability of detecting infection when present) and specificity (probability of excluding infection when absent), rendering it more reliable than alternative diagnostic tools. The average cost in diagnostic facilities ranges from 250 to 300 USD (or equivalent in local currency).
Another non-invasive option is the stool antigen test (HpSA), which detects bacterial antigens in fecal samples. The procedure entails collecting a small stool specimen, suspending it in a buffer solution, and applying three drops onto a test cassette. Results are interpreted after 10 minutes according to the manufacturer’s instructions. This test confirms active infection or evaluates the success of eradication therapy (elimination of the bacterium). Its availability in pharmacies and drugstores (price: 25–35 USD) makes it a convenient choice for patients. However, false-negative results may occur in cases of low bacterial load or shortly after treatment completion.
Serological tests measure IgG-class antibodies against H. pylori in the patient’s blood serum. A positive result indicates prior exposure to the bacterium but does not confirm active infection, as antibodies may persist for 12 months or longer post-successful eradication. While useful for epidemiological surveys or preliminary screening, this method is unsuitable for monitoring treatment outcomes.
A clinically concerning trend is the rising antibiotic resistance of H. pylori to conventionally used agents (e.g., clarithromycin, metronidazole), significantly reducing the efficacy of standard therapeutic regimens. This infection also affects pediatric populations, potentially leading to gastric and/or duodenal ulcer disease as well as chronic gastrointestinal symptoms such as abdominal pain, nausea, vomiting, or weight loss. Early diagnosis and tailored treatment selection are therefore critical to preventing complications.
Want to apply these guidelines in your daily diet?
Our smart diet generator creates a tailored meal plan in 3 minutes based on the recommendations in this article.
Literatura: Iwańczak B., Iwańczak F., „Zakażenie Helicobacter pylori u dzieci”, Borgis Nowa Pediatria 3/2002, s. 137 Albrecht P. i in., „Terapia sekwencyjna zakażeń H. pylori u dzieci – doświadczenia własne”, Postępy Nauk Medycznych, t. XXIV, nr 12, 2011, Dyrla P. i in., „Zakażenie Helicobacter pylori. Diagnostyka i leczenie”, Pediatr Med Rodz 2015, 11 (1), p. 68–74.
Diets Premium Expert
Diets Premium team expert. Specializes in nutrition plans, strength sports, and training plans.